Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: Promising options for prevention and treatment of uterine fibroids?

Molecular Nutrition and Food Research

Volumn 58, Issue 8, 2014, Pages 1667-1684

  Islam, Md Soriful ^a,b   Akhtar, Most Mauluda ^a   Ciavattini, Andrea ^a   Giannubilo, Stefano Raffaele ^a   Protic, Olga ^a   Janjusevic, Milijana ^a   Procopio, Antonio Domenico ^a   Segars, James H ^c   Castellucci, Mario ^a   Ciarmela, Pasquapina ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF RAJSHAHI   (Bangladesh)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antifibrotic; Antiproliferative; Dietary phytochemicals; Inflammation; Uterine fibroid

Indexed keywords

ANGIOGENESIS INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT MEDICINAL PRODUCT;

ANGIOGENESIS; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DIET THERAPY; DIETARY SUPPLEMENT; FEMALE; FIBROSIS; HUMAN; IMMUNOLOGY; LEIOMYOMA; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; UTERUS; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; DIETARY SUPPLEMENTS; FEMALE; FIBROSIS; HUMANS; LEIOMYOMA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHYTOCHEMICALS; UTERUS;

EID: 84905404044     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400134     Document Type: Article

References (224)

1. Ciarmela, P., Islam, M. S., Reis, F. M., Gray, P. C. et al., Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update 2011, 17, 772-790.
2. Walker, C. L., Stewart, E. A., Uterine fibroids: the elephant in the room. Science 2005, 308, 1589-1592.
3. Islam, M. S., Protic, O., Toti, P., Giannubilo, S. R. et al., Uterine leiomyoma: available medical treatments and new possible therapeutic options. J. Clin. Endocrinol. Metab. 2013, 98, 921-934.
4. Day Baird, D., Dunson, D. B., Hill, M. C., Cousins, D. et al., High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am. J. Obstet. Gynecol. 2003, 188, 100-107.
5. Marshall, L. M., Spiegelman, D., Barbieri, R. L., Goldman, M. B. et al., Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet. Gynecol. 1997, 90, 967-973.
6. Kjerulff, K. H., Langenberg, P., Seidman, J. D., Stolley, P. D. et al., Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J. Reprod. Med. 1996, 41, 483-490.
7. Moore, A. B., Flake, G. P., Swartz, C. D., Heartwell, G. et al., Association of race, age and body mass index with gross pathology of uterine fibroids. J. Reprod. Med. 2008, 53, 90-96.
8. Peddada, S. D., Laughlin, S. K., Miner, K., Guyon, J.-P. et al., Growth of uterine leiomyomata among premenopausal black and white women. Proc. Natl. Acad. Sci. USA 2008, 105, 19887-19892.
9. Weiss, G., Noorhasan, D., Schott, L. L., Powell, L. et al., Racial differences in women who have a hysterectomy for benign conditions. Women's Health Issues 2009, 19, 202-210.
10. Stewart, E. A., Uterine fibroids. Lancet 2001, 357, 293-298.
11. Farquhar, C. M., Steiner, C. A., Hysterectomy rates in the United States 1990-1997. Obstet. Gynecol. 2002, 99, 229-234.
12. Cardozo, E. R., Clark, A. D., Banks, N. K., Henne, M. B. et al., The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 2012, 206(211), e211-e219.
13. Treloar, S. A., Do, K.-A., O'Connor, V. M., O'Connor, D. T. et al., Predictors of hysterectomy: an Australian study. Am. J. Obstet. Gynecol. 1999, 180, 945-954.
14. Downes, E., Sikirica, V., Gilabert-Estelles, J., Bolge, S. C. et al., The burden of uterine fibroids in five European countries. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010, 152, 96-102.
15. Wegienka, G., Are uterine leiomyoma a consequence of a chronically inflammatory immune system? Med. Hypotheses 2012, 79, 226-231.
16. Leppert, P., Fouany, M., Segars, J. H., in: Segars, J. H. (Ed.) Understanding Uterine Fibroids-Fibroids, John Wiley & Sons, Ltd, Oxford 2013, pp. 1-10.
17. Chegini, N., Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin. Reprod. Med. 2010, 28, 180-203.
18. Marsh, E. E., Bulun, S. E., Steroid hormones and leiomyomas. Obstet. Gynecol. Clin. North Am. 2006, 33, 59-67.
19. Rein, M. S., Barbieri, R. L., Friedman, A. J., Progesterone: a critical role in the pathogenesis of uterine myomas. Am. J. Obstet. Gynecol. 1995, 172, 14-18.
20. Englund, K., Blanck, A., Gustavsson, I., Lundkvist, U. et al., Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J. Clin. Endocrinol. Metab. 1998, 83, 4092-4096.
21. Islam, M. S., Protic, O., Stortoni, P., Grechi, G. et al., Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil. Steril. 2013, 100, 178-193.
22. Friedman, A. J., Rein, M. S., Harrison-Atlas, D., Garfield, J. M. et al., A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil. Steril. 1989, 52, 728-733.
23. Andreyko, J. L., Blumenfeld, Z., Marshall, L. A., Monroe, S. E. et al., Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am. J. Obstet. Gynecol. 1988, 158, 903-910.
24. Leather, A. T., Studd, J. W. W., Watson, N. R., Holland, E. F. N., The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet. Gynecol. 1993, 81, 104-107.
25. Friedman, A. J., Hoffman, D. I., Comite, F., Browneller, R. W. et al., Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet. Gynecol. 1991, 77, 720-725.
26. Stovall, T. G., Muneyyirci-Delale, O., Summitt, R. L., Jr., Scialli, A. R., GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. The Leuprolide Study Group. Obstet. Gynecol. 1995, 86, 65-71.
27. Carbonell Esteve, J. L., Acosta, R., Heredia, B., Pérez, Y. et al., Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet. Gynecol. 2008, 112, 1029-1036.
28. Chwalisz, K., Larsen, L., Mattia-Goldberg, C., Edmonds, A. et al., A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil. Steril. 2007, 87, 1399-1412.
29. Donnez, J., Tomaszewski, J., Vázquez, F., Bouchard, P. et al., Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012, 366, 421-432.
30. Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L. et al., Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012, 366, 409-420.
31. Wiehle, R. D., Goldberg, J., Brodniewicz, T., Jarus-Dziedzic, K. et al., Effects of a new progesterone receptor modulator, CDB-4124, on fibroid size and uterine bleeding. US Obstet. Gynecol. 2008, 3, 17-20.
32. Newman, D. J., Cragg, G. M., Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
33. Chen, N.-N., Han, M., Yang, H., Yang, G.-Y. et al., Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: a systematic review of randomised clinical trials. BMC Complement. Altern. Med. 2014, 14, 2.
34. Liu, J. P., Yang, H., Xia, Y., Cardini, F., Herbal preparations for uterine fibroids. Cochrane Database Syst. Rev. 2009, 4, CD005292.
35. Zhang, D., Al-Hendy, M., Richard-Davis, G., Montgomery-Rice, V. et al., Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil. Steril. 2010, 94, 1887-1893.
36. Roshdy, E., Rajaratnam, V., Maitra, S., Sabry, M. et al., Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int. J. Women's Health 2013, 5, 477-486.
37. Malik, M., Mendoza, M., Payson, M., Catherino, W. H., Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertil. Steril. 2009, 91, 2177-2184.
38. Kim, D., Ramachandran, S., Baek, S., Kwon, S. H. et al., Induction of growth inhibition and apoptosis in human uterine leiomyoma cells by isoliquiritigenin. Reprod. Sci. 2008, 15, 552.
39. Shushan, A., Ben-Bassat, H., Mishani, E., Laufer, N. et al., Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil. Steril. 2007, 87, 127-135.
40. Catherino, W. H., Parrott, E., Segars, J., Proceedings from the National Institute of Child Health and Human Development Conference on the Uterine Fibroid Research Update Workshop. Fertil. Steril. 2011, 95, 9-12.
41. Christman, G. M., Marsh, C. A., Campbell, E. J., in: Segars, J. H. (Ed.) Counseling the Patient with Uterine Fibroids-Fibroids, John Wiley & Sons, Oxford 2012, pp. 134-144.
42. Hatthachote, P., Gillespie, J. I., Complex interactions between sex steroids and cytokines in the human pregnant myometrium: evidence for an autocrine signaling system at term. Endocrinology 1999, 140, 2533-2540.
43. Litovkin, K. V., Domenyuk, V. P., Bubnov, V. V., Zaporozhan, V. N., Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp. Oncol. 2007, 29, 295-298.
44. Luo, X., Ding, L., Xu, J., Chegini, N., Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005, 146, 1097-1118.
45. Kurachi, O., Matsuo, H., Samoto, T., Maruo, T., Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone. J. Clin. Endocrinol. Metab. 2001, 86, 2275-2280.
46. Chegini, N., Tang, X. M., Ma, C., Regulation of transforming growth factor-beta1 expression by granulocyte macrophage-colony-stimulating factor in leiomyoma and myometrial smooth muscle cells. J. Clin. Endocrinol. Metab. 1999, 84, 4138-4143.
47. Santulli, P., Even, M., Chouzenoux, S., Millischer, A.-E. et al., Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum. Reprod. 2013, 28, 2126-2133.
48. Sozen, I., Olive, D. L., Arici, A., Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata. Fertil. Steril. 1998, 69, 1095-1102.
49. Senturk, L. M., Sozen, I., Gutierrez, L., Arici, A., Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma. Am. J. Obstet. Gynecol. 2001, 184, 559-566.
50. Syssoev, K. A., Kulagina, N. V., Chukhlovin, A. B., Morozova, E. B. et al., Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. Bull. Exp. Biol. Med. 2008, 145, 84-89.
51. Cesen-Cummings, K., Houston, K. D., Copland, J. A., Moorman, V. J. et al., Uterine leiomyomas express myometrial contractile-associated proteins involved in pregnancy-related hormone signaling. J. Soc. Gynecol. Investig. 2003, 10, 11-20.
52. Khorram, O., Garthwaite, M., Magness, R. R., Endometrial and myometrial expression of nitric oxide synthase isoforms in pre-and postmenopausal women. J. Clin. Endocrinol. Metab. 1999, 84, 2226-2232.
53. Fujita, M., Histological and biochemical studies of collagen in human uterine leiomyomas. Hokkaido Igaku Zasshi 1985, 60, 602-615.
54. Leppert, P. C., Baginski, T., Prupas, C., Catherino, W. H. et al., Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil. Steril. 2004, 82(Suppl 3), 1182-1187.
55. Arici, A., Sozen, I., Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil. Steril. 2000, 73, 1006-1011.
56. Stewart, E. A., Friedman, A. J., Peck, K., Nowak, R. A., Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J. Clin. Endocrinol. Metab. 1994, 79, 900-906.
57. Norian, J. M., Malik, M., Parker, C. Y., Joseph, D. et al., Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod. Sci. 2009, 16, 1153-1164.
58. Rogers, R., Norian, J., Malik, M., Christman, G. et al., Mechanical homeostasis is altered in uterine leiomyoma. Am. J. Obstet. Gynecol. 2008, 198, 474.e471-474.e411.
59. Norian, J. M., Owen, C. M., Taboas, J., Korecki, C. et al., Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma. Matrix Biol. 2012, 31, 57-65.
60. Joseph, D. S., Malik, M., Nurudeen, S., Catherino, W. H., Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil. Steril. 2010, 93, 1500-1508.
61. Islam, M. S., Catherino, W. H., Protic, O., Janjusevic, M. et al., Role of activin-A and myostatin and their signaling pathway in human myometrial and leiomyoma cell function. J. Clin. Endocrinol. Metab. 2014, 99, 775-785.
62. Liang, M., Wang, H., Zhang, Y., Lu, S., Wang, Z., Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata. Cancer Biol. Ther. 2006, 5, 28-33.
63. Kawaguchi, K., Fujii, S., Konishi, I., Nanbu, Y. et al., Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynecol. 1989, 160, 637-641.
64. Wolanska, M., Bankowski, E., Transforming growth factor beta and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 130, 238-244.
65. Arici, A., Sozen, I., Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am. J. Obstet. Gynecol. 2003, 188, 76-83.
66. Fletcher, N. M., Saed, M. G., Abuanzeh, S., Abu-Soud, H. M. et al., Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod. Sci. 2014 [Epub ahead of print].
67. Mesquita, F. S., Dyer, S. N., Heinrich, D. A., Bulun, S. E. et al., Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. Biol. Reprod. 2010, 82, 341-351.
68. Fletcher, N. M., Saed, M. G., Abu-Soud, H. M., Al-Hendy, A. et al., Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids. J. Assist. Reprod. Genet. 2014, 30, 969-974.
69. Nair, S., Al-Hendy, A., Adipocytes enhance the proliferation of human leiomyoma cells via TNF-α proinflammatory cytokine. Reprod. Sci. 2011, 18, 1186-1192.
70. Carmeliet, P., Angiogenesis in health and disease. Nat. Med. 2003, 9, 653-660.
71. Imhof, B. A., Aurrand-Lions, M., Angiogenesis and inflammation face off. Nat. Med. 2006, 12, 171-172.
72. Chung, A. S., Lee, J., Ferrara, N., Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10, 505-514.
73. Fleischer, R., Weston, G. C., Vollenhoven, B. J., Rogers, P. A. W., Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract. Res. Clin. Obstet. Gynaecol. 2008, 22, 603-614.
74. Tal, R., Segars, J. H., The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum. Reprod. Update 2013, 20, 194-216.
75. Ciarmela, P., Carrarelli, P., Islam, M. S., Janjusevic, M. et al., Effect of ulipristal acetate on activin A expression and functions in myometrial and leiomyoma cells. Reprod. Sci. 2014.
76. Singh, B. N., Shankar, S., Srivastava, R. K., Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82, 1807-1821.
77. Zhang, D., Al-Hendy, M., Richard-Davis, G., Montgomery-Rice, V. et al., Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obstet. Gynecol. 2010, 202, 289.e281-289.e289.
78. Ozercan, I. H., Sahin, N., Akdemir, F., Onderci, M. et al., Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. Nutr. Res. 2008, 28, 92-97.
79. Wilken, R., Veena, M. S., Wang, M. B., Srivatsan, E. S., Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011, 10, 12.
80. Tsuiji, K., Takeda, T., Li, B., Wakabayashi, A. et al., Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynecol. Endocrinol. 2011, 27, 512-517.
81. Cuendet, M., Guo, J., Luo, Y., Chen, S. et al., Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res. 2010, 3, 221-232.
82. Kaufman, P. B., Duke, J. A., Brielmann, H., Boik, J. et al., A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health. J. Altern. Complement. Med. 1997, 3, 7-12.
83. Moore, A. B., Castro, L., Yu, L., Zheng, X. et al., Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum. Reprod. 2007, 22, 2623-2631.
84. Di, X., Yu, L., Moore, A. B., Castro, L. et al., A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum. Reprod. 2008, 23, 1873-1883.
85. Di, X., Andrews, D. M. K., Tucker, C. J., Yu, L. et al., A high concentration of genistein down-regulates activin A, Smad3 and other TGF-β pathway genes in human uterine leiomyoma cells. Exp. Mol. Med. 2012, 44, 281-292.
86. Sahin, K., Akdemir, F., Tuzcu, M., Sahin, N. et al., Genistein suppresses spontaneous oviduct tumorigenesis in Quail. Nutr. Cancer 2009, 61, 799-806.
87. Labinskyy, N., Csiszar, A., Veress, G., Stef, G. et al., Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr. Med. Chem. 2006, 13, 989.
88. Block, E., The chemistry of garlic and onions. Sci. Am. 1985, 252, 114-119.
89. Mo, S.-J., Son, E.-W., Rhee, D.-K., Pyo, S., Modulation of TNF-α-induced ICAM-1 expression, NO and H2O2 production by alginate, allicin and ascorbic acid in human endothelial cells. Arch. Pharm. Res. 2003, 26, 244-251.
90. Lang, A., Lahav, M., Sakhnini, E., Barshack, I. et al., Allicin inhibits spontaneous and TNF-alpha induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells. Clin. Nutr. 2004, 23, 1199-1208.
91. Gu, X., Wu, H., Fu, P., Allicin attenuates inflammation and suppresses HLA-B27 protein expression in ankylosing spondylitis mice. J. Biomed. Biotechnol. 2013, 2013, 171573.
92. Liu, C., Cao, F., Tang, Q.-Z., Yan, L. et al., Allicin protects against cardiac hypertrophy and fibrosis via attenuating reactive oxygen species-dependent signaling pathways. J. Nutr. Biochem. 2010, 21, 1238-1250.
93. Li, X.-H., Li, C.-Y., Xiang, Z.-G., Hu, J.-J. et al., Allicin ameliorates cardiac hypertrophy and fibrosis through enhancing of Nrf2 antioxidant signaling pathways. Cardiovasc. Drugs Ther. 2012, 26, 457-465.
94. Liu, Y., Qi, H., Wang, Y., Wu, M. et al., Allicin protects against myocardial apoptosis and fibrosis in streptozotocin-induced diabetic rats. Phytomedicine 2012, 19, 693-698.
95. Oommen, S., Anto, R. J., Srinivas, G., Karunagaran, D., Allicin (from garlic) induces caspase-mediated apoptosis in cancer cells. Eur. J. Pharmacol. 2004, 485, 97-103.
96. Zhang, W., Ha, M., Gong, Y., Xu, Y. et al., Allicin induces apoptosis in gastric cancer cells through activation of both extrinsic and intrinsic pathways. Oncol. Rep. 2010, 24, 1585-1592.
97. Wang, Z., Liu, Z., Cao, Z., Li, L., Allicin induces apoptosis in EL-4 cells in vitro by activation of expression of caspase-3 and-12 and up-regulation of the ratio of Bax/Bcl-2. Nat. Prod. Res. 2012, 26, 1033-1037.
98. Bat-Chen, W., Golan, T., Peri, I., Ludmer, Z. et al., Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. Nutr. Cancer 2010, 62, 947-957.
99. Cha, J. H., Choi, Y. J., Cha, S. H., Choi, C. H. et al., Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway. Oncol. Rep. 2012, 28, 41-48.
100. Hirsch, K., Danilenko, M., Giat, J., Miron, T. et al., Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr. Cancer 2000, 38, 245-254.
101. Sela, U., Brill, A., Kalchenko, V., Dashevsky, O. et al., Allicin inhibits blood vessel growth and downregulates Akt phosphorylation and actin polymerization. Nutr. Cancer 2008, 60, 412-420.
102. Vattem, D. A., Shetty, K., Biological functionality of ellagic acid: a review. J. Food Biochem. 2005, 29, 234-266.
103. Chao, P. C., Hsu, C. C., Yin, M. C., Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice. Nutr. Metab. 2009, 6, 33.
104. Umesalma, S., Sudhandiran, G., Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-kappaB, iNOS, COX-2, TNF-alpha, IL-6 in 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Basic Clin. Pharmacol. Toxicol. 2010, 107, 650-655.
105. Karlsson, S., Nånberg, E., Fjaeraa, C., Wijkander, J., Ellagic acid inhibits lipopolysaccharide-induced expression of enzymes involved in the synthesis of prostaglandin E2 in human monocytes. Br. J. Nutr. 2010, 103, 1102.
106. Marín, M., María Giner, R., Ríos, J.-L., Carmen Recio, M., Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J. Ethnopharmacol. 2013, 150, 925-934.
107. Thresiamma, K. C., Kuttan, R., Inhibition of liver fibrosis by ellagic acid. Indian J. Physiol. Pharmacol. 1996, 40, 363-366.
108. Iino, T., Tashima, K., Umeda, M., Ogawa, Y. et al., Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion. Life Sci. 2002, 70, 1139-1150.
109. Masamune, A., Satoh, M., Kikuta, K., Suzuki, N. et al., Ellagic acid blocks activation of pancreatic stellate cells. Biochem. Pharmacol. 2005, 70, 869-878.
110. Suzuki, N., Masamune, A., Kikuta, K., Watanabe, T. et al., Ellagic acid inhibits pancreatic fibrosis in male Wistar Bonn/Kobori rats. Dig. Dis. Sci. 2009, 54, 802-810.
111. Rani P. U., Kesavan, R., Ganugula, R., Kumar, P. U. et al., Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and prevents atheroma formation in streptozotocin-induced diabetic rats. J. Nutr. Biochem. 2013, 24, 1830-1839.
112. Narayanan, B. A., Geoffroy, O., Willingham, M. C., Re, G. G. et al., p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett. 1999, 136, 215-221.
113. Edderkaoui, M., Lugea, A., Hui, H., Eibl, G. et al., Ellagic acid and embelin affect key cellular components of pancreatic adenocarcinoma, cancer, stellate cells. Nutr. Cancer 2013, 65, 1232-1244.
114. Chung, Y.-C., Lu, L.-C., Tsai, M.-H., Chen, Y.-J. et al., The inhibitory effect of ellagic acid on cell growth of ovarian carcinoma cells. Evid. Based Complement. Alternat. Med. 2013, 2013, 306705.
115. Losso, J. N., Bansode, R. R., Trappey Ii, A., Bawadi, H. A. et al., In vitro anti-proliferative activities of ellagic acid. J. Nutr. Biochem. 2004, 15, 672-678.
116. Weisburg, J. H., Schuck, A. G., Reiss, S. E., Wolf, B. J. et al., Ellagic acid, a dietary polyphenol, selectively cytotoxic to HSC-2 oral carcinoma cells. Anticancer Res. 2013, 33, 1829-1836.
117. Qiu, Z., Zhou, B., Jin, L., Yu, H. et al., In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem. Toxicol. 2013, 59, 428-437.
118. Labrecque, L., Lamy, S., Chapus, A. l., Mihoubi, S. et al., Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis 2005, 26, 821-826.
119. Wang, N., Wang, Z.-Y., Mo, S.-L., Loo, T. Y. et al., Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res. Treat. 2012, 134, 943-955.
120. Aggarwal, B. B., Ichikawa, H., Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005, 4, 1201-1215.
121. Takada, Y., Andreeff, M., Aggarwal, B. B., Indole-3-carbinol suppresses NF-κB and IκBα kinase activation, causing inhibition of expression of NF-κB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells. Blood 2005, 106, 641-649.
122. Benson, J. M., Shepherd, D. M., Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol. Sci. 2013, 124, 327-338.
123. Chen, Y.-H., Dai, H.-J., Chang, H.-P., Suppression of inducible nitric oxide production by indole and isothiocyanate derivatives from Brassica plants in stimulated macrophages. Planta Med. 2003, 69, 696-700.
124. Tsai, J.-T., Liu, H.-C., Chen, Y.-H., Suppression of inflammatory mediators by cruciferous vegetable-derived indole-3-carbinol and phenylethyl isothiocyanate in lipopolysaccharide-activated macrophages. Mediators Inflamm. 2010, 2010, 293642.
125. Jiang, J., Kang, T. B., Shim, D. W., Oh, N. H. et al., Indole-3-carbinol inhibits LPS-induced inflammatory response by blocking TRIF-dependent signaling pathway in macrophages. Food Chem. Toxicol. 2013, 57, 256-261.
126. Ping, J., Li, J.-t., Liao, Z.-x., Shang, L. et al., Indole-3-carbinol inhibits hepatic stellate cells proliferation by blocking NADPH oxidase/reactive oxygen species/p38 MAPK pathway. Eur. J. Pharmacol. 2011, 650, 656-662.
127. Guan, H., Chen, C., Zhu, L., Cui, C. et al., Indole-3-carbinol blocks platelet-derived growth factor-stimulated vascular smooth muscle cell function and reduces neointima formation in vivo. J. Nutr. Biochem. 2012, 24, 62-69.
128. Marconett, C. N., Singhal, A. K., Sundar, S. N., Firestone, G. L., Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol. Cell. Endocrinol. 2012, 363, 74-84.
129. Zhang, J., Hsu, B. A., Jocelyn, C., Kinseth, B. A. et al., Indole 3 carbinol induces a G1 cell cycle arrest and inhibits prostate specific antigen production in human LNCaP prostate carcinoma cells. Cancer 2003, 98, 2511-2520.
130. Suzui, M., Inamine, M., Kaneshiro, T., Morioka, T. et al., Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int. J. Oncol. 2005, 27, 1391-1399.
131. Choi, H.-S., Cho, M.-C., Lee, H. G., Yoon, D.-Y., Indole-3-carbinol induces apoptosis through p53 and activation of caspase-8 pathway in lung cancer A549 cells. Food Chem. Toxicol. 2010, 48, 883-890.
132. Wu, H.-T., Lin, S.-H., Chen, Y.-H., Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. J. Agric. Food Chem. 2005, 53, 5164-5169.
133. Kunimasa, K., Kobayashi, T., Kaji, K., Ohta, T., Antiangiogenic effects of indole-3-carbinol and 3, 3'-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J. Nutr. 2010, 140, 1-6.
134. Wang, M.-L., Shih, C.-K., Chang, H.-P., Chen, Y.-H., Antiangiogenic activity of indole-3-carbinol in endothelial cells stimulated with activated macrophages. Food Chem. 2012, 134, 811-820.
135. Holzapfel, N. P., Holzapfel, B. M., Champ, S., Feldthusen, J. et al., The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. Int. J. Mol. Sci. 2013, 14, 14620-14646.
136. Marcotorchino, J., Romier, B., Gouranton, E., Riollet, C. et al., Lycopene attenuates LPS-induced TNF-α secretion in macrophages and inflammatory markers in adipocytes exposed to macrophage-conditioned media. Mol. Nutr. Food Res. 2010, 56, 725-732.
137. Simone, R. E., Russo, M., Catalano, A., Monego, G. et al., Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke-stimulated macrophages. PLoS One 2011, 6, e19652.
138. Wang, Y., Gao, Y., Yu, W., Jiang, Z. et al., Lycopene protects against LPS-induced proinflammatory cytokine cascade in HUVECs. Pharmazie 2013, 68, 681-684.
139. Zhou, C., Han, W., Zhang, P., Cai, M. et al., Lycopene from tomatoes partially alleviates the bleomycin-induced experimental pulmonary fibrosis in rats. Nutr. Res. 2008, 28, 122-130.
140. Kumar, A., Bagewadi, A., Keluskar, V., Singh, M., Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2007, 103, 207-213.
141. Kitade, Y., Watanabe, S., Masaki, T., Nishioka, M. et al., Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine, Sho-saiko-to. Hepatol. Res. 2002, 22, 196-205.
142. Palozza, P., E Simone, R., Catalano, A., Saraceni, F. et al., Modulation of MMP-9 pathway by lycopene in macrophages and fibroblasts exposed to cigarette smoke. Inflamm. Allergy Drug Targets 2012, 11, 36-47.
143. Karas, M., Amir, H., Fishman, D., Danilenko, M. et al., Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr. Cancer 2000, 36, 101-111.
144. Lo, H.-M., Hung, C.-F., Tseng, Y.-L., Chen, B.-H. et al., Lycopene binds PDGF-BB and inhibits PDGF-BB-induced intracellular signaling transduction pathway in rat smooth muscle cells. Biochem. Pharmacol. 2007, 74, 54-63.
145. Park, Y. O., Hwang, E. S., Moon, T. W., The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 2005, 23, 129-139.
146. Nahum, A., Hirsch, K., Danilenko, M., Watts, C. K. et al., Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27 (Kip1) in the cyclin E-cdk2 complexes. Oncogene 2001, 20, 3428-3436.
147. Palozza, P., Colangelo, M., Simone, R., Catalano, A. et al., Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis 2010, 31, 1813-1821.
148. Palozza, P., Serini, S., Boninsegna, A., Bellovino, D. et al., The growth-inhibitory effects of tomatoes digested in vitro in colon adenocarcinoma cells occur through down regulation of cyclin D1, Bcl-2 and Bcl-xL. Br. J. Nutr. 2007, 98, 789-795.
149. Elgass, S., Cooper, A., Chopra, M., Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings. Br. J. Nutr. 2012, 108, 431-439.
150. Chen, M.-L., Lin, Y.-H., Yang, C.-M., Hu, M.-L., Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. Mol. Nutr. Food Res. 2012, 56, 889-899.
151. Yang, C.-M., Yen, Y.-T., Huang, C.-S., Hu, M.-L., Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. Mol. Nutr. Food Res. 2011, 55, 606-612.
152. Hertog, M. G. L., Hollman, P. C. H., Van de Putte, B., Content of potentially anticarcinogenic flavonoids of tea infusions, wines, fruit juices. J. Agric. Food Chem. 1993, 41, 1242-1246.
153. Miean, K. H., Mohamed, S., Flavonoid (myricetin, quercetin, kaempferol, luteolin, apigenin) content of edible tropical plants. J. Agric. Food Chem. 2001, 49, 3106-3112.
154. Seeram, N. P., Lee, R., Scheuller, H. S., Heber, D., Identification of phenolic compounds in strawberries by liquid chromatography electrospray ionization mass spectroscopy. Food Chem. 2006, 97, 1-11.
155. Granado-Serrano, A. B., Martin, M. Ã., Bravo, L., Goya, L. et al., Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-kB pathway. Nutr. Cancer 2012, 64, 588-598.
156. Noh, H.-J., Kim, C.-S., Kang, J.-H., Park, J.-Y. et al., Quercetin suppresses MIP-1α-induced adipose inflammation by downregulating its receptors CCR1/CCR5 and inhibiting inflammatory signaling. J. Med. Food 2013, 17, 550-557.
157. Endale, M., Park, S.-C., Kim, S., Kim, S.-H. et al., Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. Immunobiology 2013, 218, 1452-1467.
158. Sung, M.-S., Lee, E.-G., Jeon, H.-S., Chae, H.-J. et al., Quercetin inhibits IL-1β-induced proliferation and production of MMPs, COX-2, PGE2 by rheumatoid synovial fibroblast. Inflammation 2012, 35, 1585-1594.
159. Yoon, J. S., Lee, H. J., Choi, S. H., Chang, E.-J. et al., Quercetin inhibits IL-1β-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One 2011, 6, e26261.
160. Chuang, C.-C., Martinez, K., Xie, G., Kennedy, A. et al., Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α mediated inflammation and insulin resistance in primary human adipocytes. Am. J. Clin. Nutr. 2011, 92, 1511-1521.
161. Lee, E. S., Lee, H. E., Shin, J. Y. et al., The flavonoid quercetin inhibits dimethylnitrosamine-induced liver damage in rats. J. Pharm. Pharmacol. 2003, 55, 1169-1174.
162. Baowen, Q., Yulin, Z., Xin, W., Wenjing, X. et al., A further investigation concerning correlation between anti-fibrotic effect of liposomal quercetin and inflammatory cytokines in pulmonary fibrosis. Eur. J. Pharmacol. 2010, 642, 134-139.
163. Hu, Q., Noor, M., Wong, Y. F., Hylands, P. J. et al., In vitro anti-fibrotic activities of herbal compounds and herbs. Nephrol. Dial. Transplant. 2009, 24, 3033-3041.
164. Nakamura, T., Matsushima, M., Hayashi, Y., Shibasaki, M. et al., Attenuation of transforming growth factor-beta-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am. J. Respir. Cell Mol. Biol. 2011, 44, 614-620.
165. Hernández-Ortega, L. D., Alcántar-Díaz, B. E., Ruiz-Corro, L. A., Sandoval-Rodriguez, A. et al., Quercetin improves hepatic fibrosis reducing hepatic stellate cells and regulating pro-fibrogenic/anti-fibrogenic molecules balance. J. Gastroenterol. Hepatol. 2012, 27, 1865-1872.
166. Li, M., Jiang, Y., Jing, W., Sun, B. et al., Quercetin provides greater cardioprotective effect than its glycoside derivative rutin on isoproterenol-induced cardiac fibrosis in the rat. Can. J. Physiol. Pharmacol. 2013, 91, 951-959.
167. Phan, T. T., See, P., Tran, E., Nguyen, T. T. T. et al., Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br. J. Dermatol. 2003, 148, 544-552.
168. Phan, T. T., Lim, I. J., Sun, L., Chan, S. Y. et al., Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J. Dermatol. Sci. 2003, 33, 192-194.
169. Pavanato, A., Tuñón, M. J., Sánchez-Campos, S., Marroni, C. A. et al., Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig. Dis. Sci. 2003, 48, 824-829.
170. Huynh, H., Nguyen, T. T. T., Chan, E., Tran, E., Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-α)-and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int. J. Oncol. 2003, 23, 821-829.
171. Jung, M., Bu, S. Y., Tak, K.-H., Park, J.-E. et al., Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer. Nutr. Res. Pract. 2013, 7, 439-445.
172. Yang, J.-H., Hsia, T.-C., Kuo, H.-M., Chao, P.-D. L. et al., Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metab. Dispos. 2006, 34, 296-304.
173. Choi, J.-A., Kim, J.-Y., Lee, J.-Y., Kang, C.-M. et al., Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol. 2001, 19, 837-844.
174. Kim, H.-J., Kim, S.-K., Kim, B.-S., Lee, S.-H. et al., Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J. Agric. Food Chem. 2010, 58, 8643-8650.
175. Cao, H.-H., Tse, A. K.-W., Kwan, H.-Y., Yu, H. et al., Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem. Pharmacol. 2013, 87, 424-434.
176. Gokbulut, A. A., Apohan, E., Baran, Y., Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology 2013, 18, 144-150.
177. Anand, K., Asthana, P., Kumar, A., Ambasta, R. K. et al., Quercetin mediated reduction of angiogenic markers and chaperones in DLA-induced solid tumours. Asian Pac. J. Cancer Prev. 2011, 12, 2829-2835.
178. Zhao, D., Qin, C., Fan, X., Li, Y. et al., Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur. J. Pharmacol. 2014, 723, 360-367.
179. Pratheeshkumar, P., Budhraja, A., Son, Y.-O., Wang, X. et al., Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One 2012, 7, e47516.
180. Zhong, L., Chen, F. Y., Wang, H. R., Ten, Y. et al., Effects of quercetin on morphology and VEGF secretion of leukemia cells NB4 in vitro]. Zhonghua Zhong Liu Za Zhi 2006, 28, 25.
181. Luo, H., Jiang, B.-H., King, S. M., Chen, Y. C., Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids. Nutr. Cancer 2008, 60, 800-809.
182. Santini, S. E., Basini, G., Bussolati, S., Grasselli, F., The phytoestrogen quercetin impairs steroidogenesis and angiogenesis in swine granulosa cells in vitro. J. Biomed. Biotechnol. 2009, 2009, 419891.
183. Zhang, Y., Talalay, P., Cho, C.-G., Posner, G. H., A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA 1992, 89, 2399-2403.
184. Kristal, A. R., Lampe, J. W., Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr. Cancer 2002, 42, 1-9.
185. Heiss, E., Herhaus, C., Klimo, K., Bartsch, H. et al., Nuclear factor κB is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 2001, 276, 32008-32015.
186. Lin, W., Wu, R. T., Wu, T., Khor, T.-O. et al., Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol. 2008, 76, 967-973.
187. Zhao, X. D., Zhou, Y. T., Lu, X. J., Sulforaphane enhances the activity of the Nrf2-ARE pathway and attenuates inflammation in OxyHb-induced rat vascular smooth muscle cells. Inflamm. Res. 2013, 62, 857-863.
188. Challa, A. A., Vukmirovic, M., Blackmon, J., Stefanovic, B., Withaferin-a reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. PLoS One 2012, 7, e42989.
189. Bai, Y., Cui, W., Xin, Y., Miao, X. et al., Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell. Cardiol. 2013, 57, 82-95.
190. Artaud-Macari, E., Goven, D., Brayer, S., Hamimi, A. et al., Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2013, 18, 66-79.
191. Yoo, S.-H., Lim, Y., Kim, S.-J., Yoo, K.-D. et al., Sulforaphane inhibits PDGF-induced proliferation of rat aortic vascular smooth muscle cell by up-regulation of p53 leading to G1/S cell cycle arrest. Vasc. Pharmacol. 2013, 59, 44-51.
192. Kanematsu, S., Uehara, N., Miki, H., Yoshizawa, K. et al., Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res. 2010, 30, 3381-3390.
193. Clarke, J. D., Hsu, A., Yu, Z., Dashwood, R. H. et al., Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol. Nutr. Food Res. 2011, 55, 999-1009.
194. Jeon, Y. K., Yoo, D. R., Jang, Y. H., Jang, S. Y. et al., Sulforaphane induces apoptosis in human hepatic cancer cells through inhibition of 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase4, mediated by hypoxia inducible factor-1-dependent pathway. Biochim. Biophys. Acta 2011, 1814, 1340-1348.
195. Wang, M., Chen, S., Wang, S., Sun, D. et al., Effects of phytochemicals sulforaphane on uridine diphosphate-glucuronosyltransferase expression as well as cell-cycle arrest and apoptosis in human colon cancer Caco-2 cells. Chin. J. Physiol. 2012, 55, 134-144.
196. Park, H. S., Han, M. H., Kim, G.-Y., Moon, S.-K. et al., Sulforaphane induces reactive oxygen species-mediated mitotic arrest and subsequent apoptosis in human bladder cancer 5637 cells. Food Chem. Toxicol. 2014, 64, 157-165.
197. Bertl, E., Bartsch, H., Gerhuser, C., Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol. Cancer Ther. 2006, 5, 575-585.
198. Jackson, S. J. T., Singletary, K. W., Venema, R. C., Sulforaphane suppresses angiogenesis and disrupts endothelial mitotic progression and microtubule polymerization. Vasc. Pharmacol. 2007, 46, 77-84.
199. Davis, R., Singh, K. P., Kurzrock, R., Shankar, S., Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol. Rep. 2009, 22, 1473-1478.
200. Checker, R., Sandur, S. K., Sharma, D., Patwardhan, R. S. et al., Potent anti-inflammatory activity of ursolic acid, a triterpenoid antioxidant, is mediated through suppression of NF-kB, AP-1 and NF-AT. PLoS One 2012, 7, e31318.
201. Shishodia, S., Majumdar, S., Banerjee, S., Aggarwal, B. B., Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase. Cancer Res. 2003, 63, 4375-4383.
202. Lu, J., Wu, D.-M., Zheng, Y.-l., Hu, B. et al., Ursolic acid attenuates D-galactose-induced inflammatory response in mouse prefrontal cortex through inhibiting AGEs/RAGE/NF-kB pathway activation. Cereb. Cortex 2010, 20, 2540-2548.
203. Wang, Y.-J., Lu, J., Wu, D.-M., Zheng, Z.-H. et al., Ursolic acid attenuates lipopolysaccharide-induced cognitive deficits in mouse brain through suppressing p38/NF-kB mediated inflammatory pathways. Neurobiol. Learn. Mem. 2011, 96, 156-165.
204. Kim, S.-H., Hong, J.-H., Lee, Y.-C., Ursolic acid, a potential PPARg agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, IL-17 in a mouse model of allergic asthma. Eur. J. Pharmacol. 2013, 701, 131-143.
205. Yang, J. J., Gong, Y., Shi, J., Qi, M. Y., [Study on the effect of ursolic acid (UA) on the myocardial fibrosis of experimental diabetic mice]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2013, 29, 353-356.
206. Wang, X., Ikejima, K., Kon, K., Arai, K. et al., Ursolic acid ameliorates hepatic fibrosis in the rat by specific induction of apoptosis in hepatic stellate cells. J. Hepatol. 2011, 55, 379-387.
207. Sathya, S., Sudhagar, S., Sarathkumar, B., Lakshmi, B. S., EGFR inhibition by pentacyclic triterpenes exhibit cell cycle and growth arrest in breast cancer cells. Life Sci. 2013, 95, 53-62.
208. Wang, J., Liu, L., Qiu, H., Zhang, X. et al., Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One 2013, 8, e63872.
209. Wang, X., Li, L., Wang, B., Xiang, J., Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2009, 29, 761-764.
210. Zhang, Y., Kong, C., Zeng, Y., Wang, L. et al., Ursolic acid induces PC 3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol. Carcinog. 2010, 49, 374-385.
211. Hsu, Y.-L., Kuo, P.-L., Lin, C.-C., Proliferative inhibition, cell-cycle dysregulation, induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci. 2004, 75, 2303-2316.
212. Wang, X., Zhang, F., Yang, L., Mei, Y. et al., Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo. J. Biomed. Biotechnol. 2011, 2011, 419343.
213. Yim, E.-K., Lee, M.-J., Lee, K.-H., Um, S.-J. et al., Antiproliferative and antiviral mechanisms of ursolic acid and dexamethasone in cervical carcinoma cell lines. Int. J. Gynecol. Cancer 2006, 16, 2023-2031.
214. Chadalapaka, G., Jutooru, I., McAlees, A., Stefanac, T. et al., Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives. Bioorg. Med. Chem. Lett. 2008, 18, 2633-2639.
215. Gai, L., Cai, N., Wang, L., Xu, X. et al., Ursolic acid induces apoptosis via Akt/NF-κB signaling suppression in T24 human bladder cancer cells. Mol. Med. Rep. 2013, 7, 1673-1677.
216. Cárdenas, C., Quesada, A. R., Medina, M. A., Effects of ursolic acid on different steps of the angiogenic process. Biochem. Biophys. Res. Commun. 2004, 320, 402-408.
217. Saraswati, S., Agrawal, S. S., Alhaider, A. A., Ursolic acid inhibits tumor angiogenesis and induces apoptosis through mitochondrial-dependent pathway in Ehrlich ascites carcinoma tumor. Chem. Biol. Interact. 2013, 206, 153-165.
218. Lin, J., Chen, Y., Wei, L., Hong, Z. et al., Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways. Int. J. Oncol. 2013, 43, 1666-1674.
219. Kanjoormana, M., Kuttan, G., Antiangiogenic activity of ursolic acid. Integr. Cancer Ther. 2010, 9, 224-235.
220. Chiaffarino, F., Parazzini, F., La Vecchia, C., Chatenoud, L. et al., Diet and uterine myomas. Obstet. Gynecol. 1999, 94, 395-398.
221. Wise, L. A., Radin, R. G., Palmer, J. R., Kumanyika, S. K. et al., Intake of fruit, vegetables, carotenoids in relation to risk of uterine leiomyomata. Am. J. Clin. Nutr. 2011, 94, 1620-1631.
222. Kasinski, A. L., Du, Y., Thomas, S. L., Zhao, J. et al., Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3, 5-bis(2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol. 2008, 74, 654-661.
223. Okuda, H., Ogura, K., Kato, A., Takubo, H. et al., A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther. 1998, 287, 791-799.
224. Gupta, S. C., Kim, J. H., Prasad, S., Aggarwal, B. B., Regulation of survival, proliferation, invasion, angiogenesis, metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010, 29, 405-434.